A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

February 16, 2026

Study Completion Date

July 30, 2026

Conditions

Healthy Volunteer

Interventions

DRUG

[89Zr]Zr-DFO-BIIB080

Administered as specified in the treatment arm.

DRUG

BIIB080

Administered as specified in the treatment arm.

Trial Locations (1)

UC Davis, Sacramento